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Translational aspects of the novel object recognition task in 
rats abstinent following sub-chronic treatment with 
phencyclidine (PCP): effects of modafinil and relevance to 
cognitive deficits in schizophrenia
John P . Redrobe*, Sascha Bull and Niels Plath
Department of In Vivo Neuropharmacology, Valby, Denmark
Phencyclidine (PCP) induces a behavioral syndrome in rodents that bears remarkable similarities 
to some of the core symptoms observed in schizophrenic patients, among those cognitive 
deficits.  The successful alleviation of cognitive impairments associated with schizophrenia (CIAS) 
has become a major focus of research efforts as they remain largely untreated. The aim of the 
present study was to investigate the effects of selected antipsychotic and cognition enhancing 
drugs, namely haloperidol, risperidone, donepezil, and modafinil in an animal model widely used 
in preclinical schizophrenia research. To this end, the novel object recognition (NOR) task was 
applied to rats abstinent following sub-chronic treatment with PCP . Rats were administered 
either PCP (5 mg/kg, i.p.) or vehicle twice a day for 7 days, followed by a 7-day washout period, 
before testing in NOR. Upon testing, vehicle-treated rats successfully discriminated between 
novel and familiar objects, an effect abolished in rats that had previously been exposed to PCP 
treatment. Acute treatment with modafinil (64 mg/kg, p.o.) ameliorated the PCP-induced deficit 
in novel object exploration, whereas haloperidol (0.1 mg/kg, s.c.), risperidone (0.2 mg/kg, i.p.), 
and donepezil (3 mg/kg, p.o.) were without significant effect. Given the negligible efficacy of 
haloperidol and risperidone, and the contradictory data with donepezil to treat CIAS in the clinic, 
together with the promising preliminary pro-cognitive effects of modafinil in certain subsets 
of schizophrenic patients, the sub-chronic PCP–NOR abstinence paradigm may represent an 
attractive option for the identification of potential novel treatments for CIAS.
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1999; Heckers et al., 2000; Tek et al., 2002), which is of impor-
tance for the task’s validity in relation to preclinical studies of 
schizophrenia.
Enormous efforts have been made, not least by employing vari-
ous pharmacological interventions, to mimic some of the clinically 
observed symptomatology in rodents (Neill et al., 2010; O’Tuathaigh 
and Waddington, 2010; Wilson et al., 2010). One such strategy, 
the sub-chronic administration of PCP, induces a behavioral and 
neurobiological syndrome in rodents upon cessation of treatment 
that bears a remarkable similarity to some of the core symptoms in 
schizophrenic patients, including cognitive disruption (Jentsch and 
Roth, 1999). There is substantial evidence implicating an important 
role for N-methyl-d-aspartate receptors (NMDARs) in learning 
and memory processing and that NMDAR function is aberrant 
in schizophrenia (Jentsch and Roth, 1999). NMDAR antagonists, 
such as ketamine and PCP, exacerbate psychosis in schizophrenia 
patients, and induce schizophrenia-like symptoms in healthy vol-
unteers (Lahti et al., 1995; Hetem et al., 2000; Honey et al., 2005). 
Some of the behavioral effects of PCP in humans have been shown 
to persist for several weeks following treatment cessation, which 
has been the impetus for exploring abstinence from repeated PCP 
administration as a pharmacological animal model with some rel-
evance to schizophrenia (Jentsch and Roth, 1999; Enomoto et al., 
2007; Seillier and Giuffrida, 2009). One advantage of employing 
IntroductIon
Cognitive impairments in schizophrenia are among the core symp-
toms of the disease (Sharma and Antonova, 2003), they correlate 
with functional outcome (Fett et al., 2010), and are not well treated 
with current antipsychotic therapies (Harvey and Keefe, 2001; Keefe 
et al., 2007a). In an attempt to align research efforts and aid the 
clinical  evaluation  of  potential  pro-cognitive  therapeutics,  the 
Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative has identified seven cogni-
tive domains affected in schizophrenia; namely, attention/vigilance, 
working memory, reasoning and problem solving, processing speed, 
visual learning and memory, verbal learning and memory, and 
social cognition (Green et al., 2004). Subsequently, efforts have 
been made to use the MATRICS battery to guide development of 
a preclinical cognitive test battery for research in schizophrenia 
(Young et al., 2009).
One of the preclinical assays suggested useful by MATRICS is 
the novel object recognition (NOR) task (Ennaceur and Delacour, 
1988), a test paradigm thought to reflect visual learning and rec-
ognition processing (Young et al., 2009) that has been compared 
to, among others, the visual paired-comparison task in humans 
(Clark et al., 2000; Manns et al., 2000). Moreover, schizophre-
nia patients show deficits in 2-D object recognition tasks very 
similar to the NOR paradigm (Clare et al., 1993; Aleman et al., Frontiers in Psychiatry  |  Psychopharmacology    November 2010  | Volume 1  | Article 146  |  2
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20 ± 2°C; 30–70% humidity) in Macrolon (type III) cages with 
standard sawdust bedding and environmental enrichment (plastic 
house and wooden chew blocks), with food and water available 
ad libitum (except during habituation, acquisition and retention 
trials). All animal procedures were carried out in compliance with 
the European Commission Directive 86/609/EEC and with Danish 
law regulating experiments on animals.
drugs and treatment
Phencyclidine (synthesized in-house) at 5 mg/kg was diluted in 0.9% 
saline. Haloperidol, risperidone and donepezil (Sigma, Denmark) 
were dissolved in 0.9% saline to concentrations of 0.1, 0.2, and 
3 mg/kg, respectively. Modafinil (Sequoia Research Products, UK) 
was suspended in 0.5% methylcellulose (Sigma, Denmark) to a 
concentration of 64 mg/kg.
Rats were administered sub-chronic PCP (5 mg/kg i.p. b.i.d. for 
7 days) or saline (1 ml/kg i.p. b.i.d. for 7 days) at 7 am and 7 pm, 
followed by a 7-day washout period prior to behavioral testing. 
This treatment regime is in accordance with previous methods 
(see Egerton et al., 2005; Rodefer et al., 2005, 2008). Haloperidol 
(free-base, 0.1 mg/kg, s.c.), risperidone (free-base, 0.2 mg/kg i.p.), 
donepezil (hydrochloride salt, 3 mg/kg, p.o.), and modafinil (free-
base, 64 mg/kg, p.o.) were dosed 30 min prior to the acquisition 
trial (see Figure 1A). The doses of haloperidol and risperidone were 
chosen based on in-house in vivo D2 receptor occupancy studies 
(approximately 65% at time of test session; data not shown), and 
previous published findings (Grayson et al., 2007). The doses of 
modafinil and donepezil were selected based on previous published 
findings (Waters et al., 2005; Sambeth et al., 2007; Goetghebeur and 
Dias, 2009). All doses are expressed as mg/kg free-base. All animals 
were randomly assigned to treatment groups.
apparatus and behavIoral testIng
Novel object recognition testing was performed in a rectangular 
arena surrounded by non-transparent plexi-glass walls (dimen-
sions: 95 × 45 × 50 cm). The arena was placed on a down-flow 
such a treatment-abstinence protocol is that animals are free from 
the acute motor effects of PCP that may otherwise hinder interpre-
tation of data. Another is that simple pharmacological interactions 
that could account for reversal of drug-induced effects are avoided 
(Young et al., 2009). Specifically, such a treatment regime has been 
repeatedly shown to disrupt preference for exploration of a novel 
object in the NOR task when animals are tested in an abstinent 
state (Damgaard et al., 2010; Idris et al., 2010; McLean et al., 2010; 
Snigdha et al., 2010). In addition, sub-chronic PCP administra-
tion has been demonstrated to reduce glucose utilization in the 
prefrontal cortex following termination of treatment (Pratt et al., 
2008), suggesting hypofrontality. Such effects are accompanied by 
a reduction in markers of GABAergic interneurons (e.g., parval-
bumin and Kv3.1 mRNA expression) (Abdul-Monim et al. 2007; 
Pratt et al., 2008), and deficits in cognitive domains (Goetghebeur 
and Dias, 2009; see Jentsch and Roth, 1999, for review).
Taken together, as the NOR task is generally accepted as an inter-
esting behavioral assay for measuring cognitive performance, and the 
sub-chronic administration of PCP to rodents can be considered as 
an animal model possessing some validity with respect to schizophre-
nia-like symptomatology, we decided to test a collection of clinically 
validated compounds showing varying effects in humans (Harvey 
and Keefe, 2001; Turner et al., 2004; Keefe et al., 2007a; Stip et al., 2007; 
Ribeiz et al., 2010) in our model system. The aim of the present study 
was therefore to investigate the effects of the typical antipsychotic, 
haloperidol; the atypical antipsychotic, risperidone; the acetylcho-
linesterase inhibitor (AChEi), donepezil; and the wake-promoting 
agent, modafinil, in the NOR task in rats treated sub-chronically with 
PCP. The results are discussed with respect to published preclinical 
studies and clinical findings in schizophrenic patients.
materIals and methods
anImals
Seventy-four adult male Lister Hooded rats (220–240 g at the time 
of testing) from Charles River (Germany), were housed four per 
cage under controlled conditions (12-h of light starting at 06:00; 
Figure 1 | (A) Experimental schedule: rats were treated for 7 days with vehicle or PCP (5 mg/kg, IP , b.i.d) before a 7-day washout period. Rats were then exposed to 
the novel object recognition paradigm (NOR), on days 8 + 9 following last PCP injection. (B) NOR: rats were treated with vehicle or test compound as outlined in the 
“Materials and Methods” section, and the time spent exploring a novel and familiar object was measured.www.frontiersin.org  November 2010  | Volume 1  | Article 146  |  3
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trial, ameliorated the PCP-induced deficit (P < 0.01, Bonferroni’s 
multiple comparison), whereas haloperidol (0.1 mg/kg), risperi-
done (0.2 mg/kg), and donepezil (3 mg/kg) were without significant 
effect (Figure 2). Total exploration times did not significantly differ 
across treatment groups (Figure 3).
The preference scores for the objects can be further demonstrated 
by the DI, a relative measure that corrects the difference between 
novel/familiar object exploration for total exploration activity, and 
thus allows comparison between groups (Rutten et al., 2008). Analysis 
of DI scores revealed a statistically significant group effect (one-way 
ANOVA, F(5,106) = 20.62, P < 0.001). Here, vehicle-treated animals 
displayed significantly higher index scores compared to abstinent 
air table (for ventilation) and was surrounded by a black curtain. 
Animals were habituated to the empty arena in groups of four in 
2 × 10 min sessions on day 1. On day 2, individual animals were 
introduced to the arena for an acquisition session with two identi-
cal objects (two opaque Perspex pyramids, 10 × 10 × 6 cm, or two 
domed glass paperweights, 8 × 8 × 8 cm) for 3 min (or until 20 s 
total active object exploration was achieved). The animals were 
then transferred to their homecages for a 1 h inter-trial interval 
(ITI). Following this period, the animal was re-introduced into 
the arena for the test session. Here, a triplicate of the familiar and 
a novel object were placed in the arena and the animal was allowed 
to explore during a 3-min test session. A camera mounted above 
the  arena  relayed  the  animal’s  general  behavior  (e.g.,  distance 
traveled) to a computer equipped with Ethovision tracking soft-
ware (Noldus, UK), and object interaction was scored manually by 
an experimenter blinded to the dose groups. Object exploration 
was defined as sniffing, licking or touching the object while facing 
it. Animals that did not reach a total exploration time of 15 s, after 
exploring both objects for a minimum of 2 s, were excluded from 
the data analysis. All testing was performed on day 8 or 9 after 
the last PCP injection (see Figure 1B). Treatment groups/subjects 
and novel/familiar object identity and location were randomized 
across experiments.
data presentatIon and statIstIcal analysIs
Data is presented as: (i) exploration time (s) of novel or famil-
iar object; (ii) total exploration time of novel and familiar object 
(s); (iii) discrimination index (DI), calculated as the novel object 
exploration time (Tn) minus the familiar object exploration time 
(Tf) divided by the total exploration time (Tn + Tf); (iv) total dis-
tance traveled (cm). Two experiments were performed separately 
under identical conditions (V + V, PCP + V, PCP + modafinil, 
PCP + donepezil and V + V, PCP + V, PCP + haloperidol, PCP + ris-
peridone). Statistical analysis (Student’s t-test) was then performed 
to ensure that there was no significant difference between respective 
V + V-treated groups, and also between respective PCP + V-treated 
groups. This was indeed the case and the data from the two separate 
experiments were then pooled and one-way ANOVA, followed by 
appropriate all pair-wise multiple comparison post hoc analysis 
(Bonferroni’s t-test) was used to investigate statistical differences 
between test groups (P < 0.05).
results
Three animals from the vehicle + haloperidol-treated group, and 
two animals from the vehicle + modafinil-treated group, did not 
meet the inclusion criteria and were excluded from the data analysis 
(i.e., 5 rats out of 74 total).
Analysis  of  exploration  time  of  novel  and  familiar  objects 
showed a statistically significant group effect (one-way ANOVA, 
F(11,212) = 13.31, P < 0.001). As shown in Figure 2, vehicle-treated 
rats spent more time exploring the novel over the familiar object 
during the 3 min retention trial (P < 0.001, Bonferroni’s multiple 
comparison). This effect was abolished in abstinent PCP-treated 
rats, which explored both objects to a similar degree. This indicates 
that 8- to 9-day washout following sub-chronic PCP treatment 
impairs object recognition capabilities at the 1 h ITI. Acute treat-
ment with modafinil (64 mg/kg), 30 min before the acquisition 
Figure 2 | The effects of vehicle (n = 31), haloperidol (0.1 mg/kg, n = 9), 
risperidone (0.2 mg/kg, n = 12), donepezil (3 mg/kg, n = 12), and 
modafinil (64 mg/kg, n = 10) on exploration time (s) of a novel (open 
bars) and familiar (closed bars) object in the NOr task in rats sub-
chronically treated with PCP (n = 33). Data expressed as mean + SEM. 
***P < 0.001, **P < 0.01 versus novel object exploration (one-way ANOVA 
followed by Bonferroni’s multiple comparison post hoc analysis).
Figure 3 | The effects of vehicle (n = 31), haloperidol (0.1 mg/kg, n = 9), 
risperidone (0.2 mg/kg, n = 12), donepezil (3 mg/kg, n = 12), and 
modafinil (64 mg/kg, n = 10) on total exploration time in the NOr task in 
rats sub-chronically treated with PCP (n = 33). Data expressed as 
mean + SEM.Frontiers in Psychiatry  |  Psychopharmacology    November 2010  | Volume 1  | Article 146  |  4
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dIscussIon
In the present study, we demonstrate that the wake-promoting 
agent, modafinil, possesses pro-cognitive potential when tested in 
the NOR task applied to a recognized animal model of schizophre-
nia. In accordance with previous studies (Damgaard et al., 2010; 
Idris et al., 2010; McLean et al., 2010; Snigdha et al., 2010), sub-
chronic PCP treatment induced a significant memory impairment 
in the NOR task following a 1-h ITI in rats abstinent from PCP 
for 8–9 days. This deficit was attenuated by acute treatment with 
modafinil, whereas the antipsychotic drugs haloperidol and risp-
eridone as well as the AChEi donepezil were without effect. Total 
object exploration times of objects during the retrieval phase did 
not differ across groups, although, haloperidol and risperidone-
treated animals traveled a significantly shorter distance, which 
reflects reduced exploration of the arena rather than the objects. 
To our knowledge, this is the first report outlining pro-cognitive 
potential of modafinil in the NOR task in rats that have previ-
ously been sub-chronically treated with PCP, and underlines the 
suggested clinical utility of this drug for the treatment of discrete 
cognitive deficits in schizophrenia.
Pre-clinically, modafinil has displayed pro-cognitive-like activity 
in a number of behavioral assays thought to address a variety of cog-
nitive domains in “normal” animals (see Minzenberg and Carter, 
2008 for review). These effects have been mirrored in the clinical 
setting, where modafinil has been shown to improve performance 
in certain cognitive domains in non-sleep/sleep deprived healthy 
volunteers (Pigeau et al., 1995; Turner et al., 2003; Muller et al., 
2004; Wesensten et al., 2005). However, pro-cognitive effects in 
animal models thought to reflect some aspects of a disease state are 
limited. In an eloquent study, modafinil displayed a favorable profile 
in the attentional set-shifting task in rats sub-chronically treated 
with PCP (Goetghebeur and Dias, 2009). This assay is thought to 
reflect prefrontal cortex functioning (Birrell and Brown, 2000), 
which is known to be compromised in schizophrenia patients 
presenting cognitive impairment (Patel et al., 2010). The present 
data agree with, and further extend these results and suggest that 
modafinil may also be of benefit to patients suffering from deficits 
in recognition memory processing together with impairments in 
executive function (Turner et al., 2004).
The precise mechanism of action of modafinil is a subject of 
debate. However, it has been reported that it leads to increases in 
central noradrenaline, dopamine, and histamine levels (Madras 
et al., 2006). Furthermore, modafinil decreases GABA in some 
regions, which maybe a consequence of its ability to increase cen-
tral glutamate levels (see Kumar, 2008 for review). Thus, the neu-
rochemical profile of modafinil would seem to fit with its potential 
to induce pro-cognitive effects.
Preclinical studies in the NOR task investigating the potential 
pro-cognitive activity of some currently available antipsychotics, 
e.g., risperidone, and the AChEi, donepezil, are somewhat conflict-
ing with the data presented herein. For example, Grayson et al. 
(2007)  reported  that  risperidone  reversed  a  sub-chronic  PCP-
induced deficit in NOR at a dose identical to that employed in the 
present study. However, this study was performed using female 
Lister Hooded rats, as opposed to males, and employed an ITI of 
1 min, as opposed to 1 h as used in the present study. These meth-
odological differences between studies could explain the disparity 
PCP-treated rats (P < 0.001, Bonferroni’s multiple comparison). 
Again,  modafinil  significantly  attenuated  PCP-induced  deficits 
(P < 0.01, Bonferroni multiple comparison), whereas haloperidol, 
risperidone or donepezil had no significant effect (Figure 4).
Analysis of total distance traveled during the 3-min retention trial 
revealed a statistically significant group effect (one-way ANOVA, 
F(5,106) = 6.91, P < 0.001). As shown in Figure 5, haloperidol and 
risperidone-treated groups traveled significantly shorter distances 
during the 3-min retention trial, when compared to vehicle-treated 
animals (P < 0.001 and P < 0.05, respectively, Bonferroni’s multiple 
comparison).
Figure 4 | The effects of vehicle (n = 31), haloperidol (0.1 mg/kg, n = 9), 
risperidone (0.2 mg/kg, n = 12), donepezil (3 mg/kg, n = 12), and 
modafinil (64 mg/kg, n = 10) on Di (Tn − Tf)/(Tn + Tf) in the NOr task in rats 
sub-chronically treated with PCP (n = 33). Data expressed as mean + SEM. 
###P < 0.001 versus vehicle-treated group; ***P < 0.001 versus PCP-treated 
group (one-way ANOVA followed by Bonferroni’s multiple comparison post 
hoc analysis).
Figure 5 | The effects of vehicle (n = 31), haloperidol (0.1 mg/kg, n = 9), 
risperidone (0.2 mg/kg, n = 12), donepezil (3 mg/kg, n = 12), and 
modafinil (64 mg/kg, n = 10) on distance traveled in the NOr task in rats 
sub-chronically treated with PCP (n = 33). Data expressed as mean + SEM. 
***P < 0.001, *P < 0.05 versus vehicle-treated group (one-way ANOVA 
followed by Bonferroni’s multiple comparison post hoc analysis).www.frontiersin.org  November 2010  | Volume 1  | Article 146  |  5
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  contradictory findings. A recent review gathered available data 
on clinical trials of modafinil treatment for cognitive deficits in 
schizophrenia (Saavedra-Velez et al., 2009). Of the six reviewed 
studies, three trials showed promising effects of modafinil in several 
cognitive domains, including recognition memory. Other domains 
benefiting from modafinil included short-term memory, working 
memory, attention, and executive function (Rosenthal and Bryant, 
2004; Turner et al., 2004; Spence et al., 2005). Functional correlates, 
as assessed by imaging, were identified in two studies in discrete 
brain areas linked to working memory processing (Spence et al., 
2005; Hunter et al., 2006). A potential concern was highlighted 
in three studies (Sevy et al., 2005; Spence et al., 2005; Pierre et al., 
2007), where a slight propensity for psychosis exacerbation was 
observed (6.0% versus 2.9% in modafinil- and placebo-treated 
groups, respectively). Two of these studies failed to show any cog-
nitive benefit of modafinil (Sevy et al., 2005; Pierre et al., 2007).
It has been suggested that the positive effects of modafinil on 
cognitive processing, at least in healthy volunteers, maybe lim-
ited to “lower-performing” individuals (Muller et al., 2004), or to 
individuals with lower IQ (Randall et al., 2005). This may be an 
important observation with respect to the choice of schizophrenic 
patients to be included in clinical trials. A consideration could be 
that patients could be better segmented and only patients display-
ing cognitive deficits across similar domains should be included in 
clinical investigations, although it is understood that such a sugges-
tion may infer considerably more work for the trial organizers in 
finding such patients. In addition, the inclusion of patients show-
ing deficits in domains where modafinil has proven beneficial in 
preclinical models/assays could also serve to increase the likelihood 
of success. Overall, although the clinical data on modafinil looks 
encouraging across several cognitive domains, the preliminary 
nature of the studies to date, i.e., small sample sizes together with 
methodological differences between trials, make it difficult to draw 
firm conclusions.
In summary, given the negligible efficacy of haloperidol and 
risperidone, the contradictory data with donepezil to treat cog-
nitive  symptoms  associated  with  schizophrenia  in  the  clinic 
(Harvey and Keefe, 2001; Keefe et al., 2007a), and the promising 
preliminary pro-cognitive effects of modafinil in certain subsets 
of schizophrenic patients (Morein-Zamir et al., 2007), the sub-
chronic PCP–NOR abstinence paradigm may represent an attrac-
tive option for the identification of potential novel treatments. 
Only with well-powered, randomized placebo-controlled trials 
incorporating validated test batteries, and in connection with 
global functional outcome measures, will modafinil’s efficacy and 
effectiveness as a treatment for cognitive deficits in schizophrenia 
be confirmed.
in the effects of risperidone. On the other hand, our data with 
haloperidol is in agreement with that of Grayson et al. (2007). 
Furthermore, Kunitachi et al. (2009) showed that donepezil was 
capable of reversing a sub-chronic PCP-induced deficit in NOR 
performance. However, this study was performed using male ICR 
mice, employed an ITI of 24 h, and donepezil was administered once 
a day for 14 days, as opposed to an acute injection 30 min before 
acquisition used in the present study. A more recent study also 
outlined some positive effects of donepezil in an object-place-con-
text recognition assay in rats sub-chronically treated with PCP (Le 
Cozannet et al., 2010). Donepezil was shown to improve perform-
ance in “normal” animals, and to attenuate PCP-induced deficits 
at a 5 min, but not a 10 min, ITI following chronic administra-
tion. Again, methodological differences between the studies could 
explain the discrepancies in the data. However, it cannot be ruled 
out that donepezil may have shown positive effects in the present 
study if a chronic treatment regimen had been employed.
Unfortunately, methodological differences across laboratories 
are a fact of life within preclinical research and demand either 
utilization of standardized protocols or introduction of additional 
control readouts that allow more stringent comparison between 
labs. Discrepancies in experimental set ups are not only confined 
to the preclinical laboratory, as now will be discussed with respect 
to clinical investigations.
Clinical studies investigating the potential pro-cognitive activity 
of typical (e.g., haloperidol) and atypical (e.g., risperidone) antipsy-
chotics in schizophrenic patients have yielded negligible or no effects, 
in agreement with the present study. Thus, treatment with antipsy-
chotic medication is associated with slight to moderate improvement 
in cognitive test performance of patients who have schizophreni-
form disorder, who are in their first episode of schizophrenia, or 
who are chronically ill (Harvey and Keefe, 2001; Keefe et al., 2007a; 
Davidson et al., 2009). In addition, the magnitude of improvement 
does not differ between treatment with haloperidol and treatment 
with second-generation antipsychotics. (Harvey and Keefe, 2001; 
Keefe et al., 2007a; Davidson et al., 2009). AChEIs have also been 
tested in initial clinical trials in schizophrenia, with some studies 
suggesting a moderate beneficial effect in general cognitive impair-
ment when administered as an add-on treatment (Buchanan et al., 
2003; Lee et al., 2007; Chung et al., 2009), while others showed no 
benefits (Friedman et al., 2002; Tugal et al., 2004; Keefe et al., 2007b). 
Therefore, it has been generally accepted that there is considerable 
room for improvement in the treatment of cognitive symptoms, and 
this is reflected in the amount of research being performed.
As a result of the encouraging preclinical data pointing toward 
a possible pro-cognitive effect of modafinil, several clinical stud-
ies in schizophrenic patients have been initiated with somewhat Frontiers in Psychiatry  |  Psychopharmacology    November 2010  | Volume 1  | Article 146  |  6
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